Intravitreal injections, antibiotics and endophthalmitis

Eye (Basingstoke)

Volumn 27, Issue 12, 2013, Pages 1426-1427

  Bhavsar, A R ^a   Sandler, D R ^b   Gentile, R C ^c,d,e  

^a Phillips Eye Institute   (United States)

^b MIDWESTERN UNIVERSITY   (United States)

^c NEW YORK EYE AND EAR INFIRMARY   (United States)

^d NEW YORK MEDICAL COLLEGE   (United States)

^e WINTHROP UNIVERSITY HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; POVIDONE IODINE;

ENDOPHTHALMITIS; EYE SURGERY; HUMAN; INTRAVITREAL DRUG ADMINISTRATION; LETTER; QUESTIONNAIRE; RISK FACTOR;

ANTI-BACTERIAL AGENTS; ANTIBODIES, MONOCLONAL, HUMANIZED; ENDOPHTHALMITIS; FEMALE; HUMANS; MALE; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VITRECTOMY;

EID: 84890453947     PISSN: 0950222X     EISSN: 14765454     Source Type: Journal    
DOI: 10.1038/eye.2013.225     Document Type: Letter

References (3)

1. Lyall DAM, Tey A, Foot B, Roxburgh STD, Virdi M, Robertson C et al. Post-intravitreal anti-VEGF endophthalmitis in the United Kingdom: incidence, features, risk factors, and outcomes. Eye 2012; 26: 1517-1526.
2. Foot BG, Stanford MR. Questioning questionnaires. Eye (Lond) 2001; 15: 693-694.
3. Speaker MG, Menikoff JA. Prophylaxis of endophthalmitis with topical povidone-iodine. Ophthalmology 1991; 98(12): 1769-1775.